Neuroinflammation in Asymptomatic Carotid Artery Disease - Imaging Substudy
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This clinical imaging substudy will use the small molecule translocator protein (TSPO)
ligand, Fludeoxyglucose(18F)-labeled DPA-714, to compare neuroinflammation in individuals
with high or low grade asymptomatic carotid artery stenosis (aCAD) who are participating in
the separate Neuroinflammation in Asymptomatic Carotid Artery Disease study lead by Dr. Ron
Lazar (IRB-300007806). The positron emission tomography (PET) tracer [18F]DPA-714 binds to
the 18 kDa translocator protein (TSPO, also known as the peripheral benzodiazepine receptor)
in the mitochondria of activated microglia/macrophages and provides a non-invasive measure of
neuroinflammation.